Scientific name: Lysergic acid diethylamide (LSD-25)

Common names: LSD, acid, lysergide

Chemical class: Ergot alkaloid derivative, specifically a lysergic acid amide (ergolamide class). Its molecular formula is C₂₀H₂₅N₃O.

Substance type: Fully synthetic. LSD does not occur in nature. Its parent structure, lysergic acid, derives from ergot alkaloids produced by Claviceps purpurea, a fungus that parasitizes rye and other grains, but LSD itself is a laboratory creation.

Appearance: Colorless or white crystalline powder, odorless, and nearly tasteless. In its pure form, it degrades under UV light and heat but remains stable in darkness at room temperature.

Taxonomic position: LSD belongs to the classic serotonergic psychedelics, compounds whose primary effects arise from agonism at the serotonin 5-HT2A receptor. Within this group, it sits alongside psilocin (from mushrooms) and mescaline (from cacti), though its fully synthetic origin and ergoline molecular scaffold set it apart structurally.

LSD is most commonly encountered as blotter paper: small squares of perforated paper onto which the compound has been absorbed. Other forms include liquid solutions (LSD dissolved in ethanol or water), gelatin capsules, and, rarely, crystalline powder. The compound is nearly always taken orally or sublingually.

Clinical contexts

In current clinical trials (including the Compass Pathways COMP360 protocol), LSD is administered as a precisely measured liquid or tablet in a controlled medical setting. Participants undergo weeks of psychological preparation and months of structured integration. Medical monitoring continues throughout the session. These protocols represent the most carefully controlled encounter with LSD available today.

Informal contexts

Outside clinical research, people encounter LSD in a range of settings: personal exploration, social gatherings, creative practice, and micro-protocols (repeated low-level ingestion intended for cognitive or mood support, though evidence for efficacy remains limited). Approximately 4 to 5 percent of US adults report lifetime use.

How route shapes experience

The route of administration primarily affects onset and intensity trajectory rather than the fundamental character of the experience. Oral or sublingual ingestion produces a gradual onset over 20 to 45 minutes, with effects building over 2 to 3 hours and lasting 8 to 12 hours total. Intravenous administration (used only in historical research settings) compresses the timeline dramatically, with onset within minutes but shorter overall duration.

Purity concerns

A significant safety consideration: studies have found that 10 to 20 percent of blotter sold as LSD in some markets contains NBOMe compounds instead, substances with a substantially higher toxicity profile. Reagent testing (particularly the Ehrlich test, which produces a purple color in the presence of indole compounds like LSD and no color for NBOMe) provides a basic screening tool, though it cannot confirm the specific compound or its purity.

LSD has no ancient lineage. It emerged from a laboratory bench in Basel, Switzerland, on April 16, 1938, when a 32-year-old chemist named Albert Hofmann synthesized it as the 25th compound in a systematic series of lysergic acid derivatives. He was looking for respiratory and circulatory stimulants. The new compound showed modest interest in animal tests and was shelved.

Five years later, on another April afternoon, Hofmann returned to LSD-25, suspecting he had missed something. During the synthesis he inadvertently absorbed a trace of the compound, likely through skin contact. By 4:20 PM he noted unusual sensations in his laboratory notebook. He left work, bicycled home through the streets of Basel, and entered a state of profound perceptual alteration that lasted hours. On May 25, 1943, he intentionally ingested a measured quantity, confirming his suspicion. This was the first controlled human encounter with a psychedelic compound in the modern sense.

By 1947, Sandoz Pharmaceuticals had patented LSD and began distributing it under the brand name Delysid to research institutions across Europe. Psychiatrists in Switzerland, Germany, and France explored its potential as a tool for understanding psychosis and facilitating psychotherapy. In Canada, Humphry Osmond and Abram Hoffer investigated LSD-assisted treatment for alcoholism, with early results that showed genuine promise.

But during the same decade, the compound entered darker territory. The CIA's MKULTRA program administered LSD to unwitting subjects in psychiatric hospitals and prisons, seeking applications in interrogation and mind control. The program produced no useful intelligence and caused significant psychological harm, representing one of the most serious ethical violations in medical research history.

Through the late 1950s and early 1960s, LSD moved beyond clinical walls. Artists, writers, and intellectuals in San Francisco and New York began experimenting outside medical contexts. Timothy Leary's public advocacy accelerated this shift, and by 1966, LSD had become entangled with the counterculture movement, anti-war activism, and rising public anxiety about social disruption. California banned possession in May 1966. The federal government placed LSD on Schedule I in October of the same year. Most countries followed within a few years.

For three decades, serious research effectively ceased. The revival began quietly in the early 2000s, as neuroscientists at institutions like Johns Hopkins and Imperial College London reopened investigation into psychedelic compounds. By 2024, Compass Pathways had received FDA Breakthrough Therapy designation for LSD-assisted treatment of treatment-resistant depression, and multiple Phase 2 and Phase 3 trials were underway.

LSD does not damage organs. It does not cause neuronal death. No deaths from direct LSD-induced cardiovascular effects have been documented in modern medical literature. The actual risks are primarily psychological and situational, and they deserve honest attention rather than exaggeration or dismissal.

Psychological risks

Acute psychological distress during the session occurs in an estimated 20 to 30 percent of recreational users, characterized by anxiety, panic, or overwhelming fear. In the vast majority of cases, it resolves as effects wear off (within 6 to 12 hours). Reassurance, a safe environment, and time are usually sufficient.

LSD does not cause psychotic illness in neurologically typical individuals. In people with pre-existing psychotic vulnerability (often undiagnosed schizophrenia spectrum or bipolar I disorder), it can precipitate an acute episode, similar to how extreme stress can activate latent vulnerability. Screening for personal and family psychiatric history is considered essential.

Hallucinogen persisting perceptual disorder (HPPD)

Some people report brief visual disturbances (geometric patterns, brightened colors, trailing) occurring days or weeks after the experience without re-exposure. Recognized in the DSM-5, HPPD prevalence estimates vary widely. Most cases are mild and resolve over time. The mechanism remains unclear.

Physical considerations

Heart rate and blood pressure increase modestly. For healthy individuals, this presents minimal concern. For those with uncontrolled hypertension, cardiac arrhythmias, or coronary artery disease, these changes represent contraindications. Pregnancy is also considered an absolute contraindication due to insufficient safety data.

Drug interactions

Combinations with MAOIs carry risk of severe serotonergic overstimulation. SSRIs and SNRIs may theoretically enhance effects, though clinical documentation is limited. Lithium has been associated with intensified effects in case reports. Benzodiazepines are sometimes used as a rescue intervention during acute distress.

The adulterant problem

Perhaps the most concrete danger in uncontrolled settings is not LSD itself but what is sold in its place. NBOMe compounds, found in an estimated 10 to 20 percent of blotter in some markets, have caused seizures, severe vasoconstriction, and deaths. Reagent testing provides a basic screening tool.

Set, setting, and support

Many risks are modulated by context. A person's psychological state, the physical environment, the presence of trusted support, and the absence of time pressure all shape the likelihood of difficult experiences. These do not ensure safety, but they represent the most well-established variables for risk reduction.

The experience does not end when the effects wear off. In many ways, the more consequential phase begins afterward, as the mind works to absorb what it encountered.

Integration is not a technique. It is a practice of attention, a willingness to sit with what surfaced and to let meaning emerge without forcing it. Some insights may feel vivid in the moment but dissolve upon reflection. Others arrive quietly, days later, as shifted priorities or softened patterns of thought. Both responses are normal.

In the immediate aftermath

The hours following the experience often carry residual emotional openness or sensitivity. Sleep may be delayed despite physical tiredness. Many people find it helpful to rest, to be in gentle company, and to resist the impulse to immediately interpret or narrativize everything that happened. Talking through the experience with someone who was present, or simply sitting with it in silence, can both serve the process.

In the days and weeks that follow

Journaling is one of the most commonly reported integration practices, not because it is prescribed, but because the experience often generates material that feels worth recording before it fades. Some people find that movement, time in nature, or creative expression helps them process what arose. Others seek conversation with a therapist, a trusted friend, or a peer support community.

In clinical settings, integration is formalized: the Compass Pathways protocol includes nine integration sessions over six weeks, guided by a therapist, moving from emotional processing to meaning-making to long-term perspective. This structure reflects a recognition that the experience alone is not the intervention. The work of connecting insight to daily life is what gives it staying power.

What integration is not

It is not a checklist, and it is not a frame that should minimize difficult material. If the experience surfaced something painful or destabilizing, that material deserves careful attention, ideally with professional support rather than self-guided processing alone.

Some people feel a clear shift immediately. For others, the effects of integration are slow and subtle, revealing themselves over weeks or months. Both timelines are valid.

Microdosing LSD involves taking 5 to 15 micrograms -- roughly one-tenth of a standard dose -- at regular intervals. At these quantities, the characteristic features of an LSD experience (visual phenomena, ego dissolution, time distortion) are absent. What remains is a subtle alteration in attentional quality and mood that most people can notice without it being disruptive.

Common protocols

The Fadiman protocol (one dosing day followed by two rest days) was originally developed with LSD in mind. LSD's extended half-life of 8-12 hours means effects can persist well into the evening, which is one reason the protocol includes substantial off-days. Doses are typically calibrated by dividing a known quantity precisely -- volumetric dosing in distilled water is the most reliable method.

What to expect

Reports are highly individual. Some people describe a gentle brightening of focus or mood on dosing days; others notice little or experience mild anxiety. Controlled research suggests expectation accounts for a meaningful share of reported benefits -- though neurobiological effects at these doses are measurable in brain imaging studies.

Practical considerations

LSD's long half-life is the primary practical factor distinguishing it from psilocybin in microdosing contexts. Dosing in the morning is important -- afternoon doses frequently disrupt sleep onset. Tolerance develops quickly, making consistent off-days essential. At true microdose levels, HPPD risk appears to be low, though anyone with a history of psychosis or hallucinogen-related anxiety should approach with particular caution.

For protocols, evidence, and integration practices, see the dedicated Microdosing guide.

LSD is entirely synthetic. There is no plant to overharvest, no endangered species to protect, no indigenous ceremony to honor or accidentally appropriate. In this sense, many of the ethical considerations that surround plant-based psychedelics do not apply in the same way.

But the absence of ecological concerns does not mean an absence of ethical ones.

Access and equity

LSD is illegal in virtually every country. Research exemptions exist, but they are narrow: an estimated 100 to 200 people globally have legal therapeutic access through clinical trials in any given year. If LSD-assisted therapy eventually receives regulatory approval, projected costs ($3,000 to $10,000 per session, based on comparable psilocybin therapy pricing) risk creating a treatment available primarily to the wealthy. Clinical trials have historically enrolled predominantly white, affluent participants through university networks, raising questions about whose experiences and outcomes are shaping the science.

The weight of prohibition

LSD's legal history is inseparable from the politics of the 1960s counterculture. Its placement on Schedule I in 1966 was driven as much by social anxiety and political pressure as by pharmacological evidence. The War on Drugs enforcement that followed disproportionately affected low-income communities and communities of color. Any conversation about LSD's future therapeutic role must reckon with this history rather than treat legalization as a neutral scientific inevitability.

Commercialization tensions

As private companies invest in LSD-assisted therapy protocols, questions of intellectual property, pricing, and public benefit come into focus. The compound itself is long out of patent, but specific therapeutic protocols can be patented, creating potential monopolies on access. Advocacy for open-access protocols, insurance coverage, and community-based therapeutic models represents one response to these tensions.